A Phase 3 interventional study of Rosuvastatin 20 Mg Oral Tablet and Coenzyme Q10 100 MG Oral Capsule in Nonalcoholic Steatohepatitis, sponsored by Tanta University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-16.
Sponsored by Tanta University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University — 6 open to participants now, 8 under way, 4 of them phase 3. Non-alcoholic Fatty Liver Disease · Tanta University.
Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 7th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →6 of the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University are open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18–65
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
Tanta University · Sites in Egypt
Ages 18–60
Tanta University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5 · Phase 4 2
First in 2019; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 58 across the 12 interventional studies, 500 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Non-alcoholic Fatty Liver Disease by Tanta University that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07900100Phase 3Tanta UniversityEvaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients. | 2027-06-20 |
| NCT07900087Phase 3Tanta UniversityEvaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients | 2027-08-01 |
| NCT06863376Tanta UniversityEvaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients | 2027-03-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be a randomized, controlled, parallel study that aims to evaluate the efficacy and safety of Rosuvastatin versus Coenzyme Q10 on nonalcoholic steatohepatitis patients.
Group 1(n=23): patients will receive Rosuvastatin 20mg/day orally
Group 2(n=23): patients will receive Coenzyme Q10 100 mg/day orally
The patients will be selected from community awareness campaigns about NASH in Alexandria , Egypt . Written informed consent will be obtained from all patients. This study will be approved by the Research Ethics Committee of Tanta University and Alexandria university.
The study duration will be 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive Rosuvastatin 20mg/day orally for 3 months
Drug: Rosuvastatin 20 Mg Oral Tablet
Patients will receive Coenzyme Q10 100 mg/day orally for 3 months
Drug: Coenzyme Q10 100 MG Oral Capsule
Rosuvastatin 20 mg will be administered orally once daily for 3 Months
Coenzyme Q10 100 mg will be administered orally once daily for 3 Months
Change in liver stiffness measurement (LSM)
LSM will be assessed by Fibro scan
Time frame: At baseline and 12th week
Change in ultrasound score
Ultrasound score will be assessed by Ultrasonography
Time frame: At baseline and 12th week
Demonstrate changes in Alanine aminotransferase (ALT)
Alanine aminotransferase (ALT) in U/L
Time frame: At baseline and 12th week
Demonstrate changes in Aspartate aminotransferase (AST)
Aspartate aminotransferase (AST) in U/L
Time frame: At baseline and 12th week
Demonstrate changes in Alkaline phosphatase (ALP)
Alkaline phosphatase (ALP) in U/L
Time frame: At baseline and 12th week
Demonstrate changes in ɤ-glutamyltranspeptidase (GGT)
ɤ-glutamyltranspeptidase (GGT) in U/L
Time frame: At baseline and 12th week
Demonstrate changes in Direct bilirubin
Direct bilirubin in mg/dl
Time frame: At baseline and 12th week
Demonstrate changes in the Lipid values
Total cholesterol(TC) in mg/dl , Triglycerides(TG) in mg/dl , LDL-Cholesterol in mg/dl , HDL-Cholesterol in mg/dl
Time frame: At baseline and 12th week
Demonstrate changes in the body weight and body mass index (BMI)
BMI in kg/m\^2 will be calculated using the formula: BMI= \[Weight (kg)/Height (m2)\].
Time frame: At baseline and 12th week
Demonstrate changes in the Inflammatory marker : CRP
C-reactive protein in mg/L
Time frame: At baseline and 12th week
Demonstrate changes in Serum cytokeratin 18 (Ck-18)
Serum cytokeratin 18 (Ck-18) will be determined by Enzyme-linked Immunosorbent assay kits.
Time frame: At baseline and 12th week
Demonstrate changes in Serum transforming growth factor-beta1 (TGF-β1)
Serum transforming growth factor-beta1 (TGF-β1) will be determined by Enzyme-linked Immunosorbent assay kits.
Time frame: At baseline and 12th week
Serum Retinol binding protein 4 (RBP-4)
Serum Retinol binding protein 4 (RBP-4) will be determined by Enzyme-linked Immunosorbent assay kits.
Time frame: At baseline and 12th week
No study locations are listed for this record.
Start is estimated for Jun 2023; primary completion for Feb 2024, 8 months later.
Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Coenzyme Q10
Non-alcoholic Fatty Liver Disease →